Inclusive of all taxes
HERTRAZ 440 MG (Trastuzumab Injection) is a targeted biopharmaceutical product used in the treatment of HER2-positive breast cancer and gastric cancers. Trastuzumab is a monoclonal antibody that specifically binds to the HER2 receptors on the surface of cancer cells, inhibiting proliferation and inducing immune-mediated cytotoxicity. This injection is designed for intravenous administration under the guidance of oncologists and healthcare professionals in clinical and hospital settings. HERTRAZ 440 MG plays a critical role in improving survival rates and reducing tumor progression in eligible patients with HER2 overexpressing tumors. The product is manufactured under stringent quality control and complies with pharmaceutical standards essential for oncology therapeutics.
Key Features
| Features | Description |
|---|---|
| Active Ingredient | Trastuzumab |
| Dosage Strength | 440 MG per vial |
| Formulation | Sterile Injectable Solution |
| Therapeutic Use | Treatment of HER2-positive breast and gastric cancers |
| Administration Route | Intravenous Injection |
| Mechanism of Action | Monoclonal antibody targeting HER2 receptors |
| Packaging | Single-use vial |
| Storage Condition | 2°C to 8°C (Refrigerated) |
| Attributes | Description |
|---|---|
| Molecular Weight | Approximately 145 kDa |
| pH | Approximately 6.0 |
| Volume per Vial | 50 ml solution containing 440 mg trastuzumab |
| Shelf Life | 24 months from manufacturing date |
| Excipients | Histidine, trehalose, polysorbate 20, water for injection |
| Storage Instructions | Protect from light and do not freeze |
| Manufacturing Compliance | Produced in GMP-certified facility |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
HERTRAZ 440 MG is indicated for the treatment of HER2-positive breast cancer and HER2-positive gastric cancer.
HERTRAZ 440 MG should be stored refrigerated between 2°C to 8°C, protected from light, and must not be frozen.
No, HERTRAZ 440 MG must be administered intravenously under the supervision of qualified healthcare professionals in a clinical setting.
HERTRAZ 440 MG works as a monoclonal antibody that binds to HER2 receptors on cancer cells, blocking growth signals and activating immune system mechanisms to destroy these cells.
HERTRAZ 440 MG is a biosimilar product; however, interchangeability should be determined by the healthcare provider considering patient condition and regulatory approvals.
Inclusive of all taxes
You Save: 0
